United States:
Outlook 2017 for Health Care and Life Sciences—What to Expect from HHS, FDA and Congress (podcast)
29 December 2016
Ropes & Gray LLP
To print this article, all you need is to be registered or login on Mondaq.com.
What impact will the incoming Trump administration have on the
2017 health care and life sciences regulatory outlook? In this
two-part podcast, The New HHS: Tom Price and Value-Based Health
Care and The New FDA: Product Development, Pricing and
Beyond, Washington, D.C.-based partners Tom Bulleit (health
care) and Al Cacozza (life sciences) offer their perspectives on
what might lie ahead regarding:
- Rep. Tom Price's nomination to head HHS
- Value-based health care
- Developments at the FDA
- Drug pricing
To learn more about potential regulatory and enforcement
developments emanating from Washington, visit
Capital Insights.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Food, Drugs, Healthcare, Life Sciences from United States
Healthcare Policy Developments To Watch In 2024
Crowell & Moring LLP
The ever-changing healthcare policy landscape will witness at the federal level regulatory changes driven by the need to transform healthcare delivery, quality and innovation.
The FDA And The Future Of AI Oversight
Manatt, Phelps & Phillips LLP
In January 2024, the U.S. Government Accountability Office (GAO) issued a report highlighting current obstacles to the U.S. Food and Drug Administration's (FDA) timely and effective regulation...